All patients
subjects at risk
chloroquine and derivatives in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
0.69 [0.28 ; 1.68 ] FACCT Trial, 2021 1 0% 254 NA not evaluable deathsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
FACCT Trial, 2021 0.96 [0.44; 2.08]
HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89]
NCT04342650, 2020 0.95 [0.02; 48.42]
Zhaowei Chen, 2020 1.00 [0.02; 52.04]
1.08 [0.59 ; 1.98 ] ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, FACCT Trial, 2021, HC-nCoV (Shanghai), 2020, NCT04342650, 2020, Zhaowei Chen, 2020 6 0% 860 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
Kamran, 2020 0.95 [0.32; 2.78]
Zhaowei Chen, 2020 0.11 [0.01; 2.19]
1.02 [0.54 ; 1.93 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Kamran, 2020, Zhaowei Chen, 2020 3 18% 894 moderate not evaluable clinical improvementdetailed results Tang, 2020 1.01 [0.59; 1.74]
1.01 [0.59 ; 1.74 ] Tang, 2020 1 0% 119 NA not evaluable clinical improvement (14-day)detailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
0.83 [0.47 ; 1.44 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1 0% 448 NA not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
Tang, 2020 1.01 [0.59; 1.74]
0.88 [0.67 ; 1.16 ] FACCT Trial, 2021, Tang, 2020 2 0% 373 moderate not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
0.88 [0.64 ; 1.21 ] FACCT Trial, 2021 1 0% 254 NA not evaluable radiologic improvement (7-day)detailed results Zhaowei Chen, 2020 3.43 [1.10; 10.70]
3.43 [1.10 ; 10.70 ] Zhaowei Chen, 2020 1 0% 62 NA not evaluable viral clearance detailed results HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75]
Tang, 2020 0.85 [0.58; 1.23]
0.83 [0.57 ; 1.21 ] HC-nCoV (Shanghai), 2020, Tang, 2020 2 0% 180 serious not evaluable viral clearance (time to event analysis only)detailed results Tang, 2020 0.85 [0.58; 1.23]
0.85 [0.58 ; 1.23 ] Tang, 2020 1 0% 150 NA not evaluable ICU admissiondetailed results FACCT Trial, 2021 1.42 [0.79; 2.55]
1.42 [0.79 ; 2.55 ] FACCT Trial, 2021 1 0% 254 NA not evaluable adverse eventsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01]
1.54 [0.58 ; 4.10 ] ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020 3 25% 392 serious not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-19 01:32 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 508,656,657,832
- roots T: 290
